- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07680049
The Mediating Role of Balance in the Relationship Between Fatigue and Fear of Falling in Individuals With Multiple Sclerosis
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Multiple sclerosis (MS) is a chronic demyelinating and neurodegenerative disease of the central nervous system that frequently leads to fatigue, balance impairment, and fear of falling. These symptoms negatively affect mobility, independence, participation in daily activities, and quality of life. Fatigue is one of the most common and disabling symptoms in individuals with MS and may contribute to impaired balance and an increased risk of falls.
Fear of falling is highly prevalent in people with MS and is associated with reduced physical activity, activity avoidance, and functional decline. Balance impairment is another common manifestation of MS and may represent an important mechanism linking fatigue to fear of falling. However, although fatigue, balance, and fear of falling have been investigated separately, the mediating role of balance in the relationship between fatigue and fear of falling has not been sufficiently explored.
The aim of this cross-sectional observational study is to investigate whether balance mediates the relationship between fatigue and fear of falling in individuals with multiple sclerosis. Fatigue will be assessed using the Fatigue Severity Scale (FSS), balance performance will be evaluated using the Mini-Balance Evaluation Systems Test (Mini-BESTest), and fear of falling will be measured using the Falls Efficacy Scale-International (FES-I).
The findings of this study are expected to improve the understanding of the mechanisms underlying fear of falling in individuals with MS and provide evidence to support the development of rehabilitation programs targeting balance to reduce fear of falling and improve functional outcomes.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Uskudar
-
Istanbul, Uskudar, Turquie (Türkiye), 34662
- Uskudar University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Age 18-65 years
- Neurologist-confirmed MS diagnosis
- No relapse within the previous 30 days
- Ability to walk independently or with an assistive device
- Ability to understand instructions
- Voluntary participation
Exclusion Criteria:
- Recent MS relapse
- Severe vestibular disorder
- Other neurological diseases
- Severe orthopedic conditions affecting mobility
- Recent lower extremity surgery or trauma
- Cardiopulmonary conditions limiting assessment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Individuals with Multiple Sclerosis
Adults diagnosed with multiple sclerosis who meet the eligibility criteria will participate in a single assessment session to evaluate fatigue, balance, and fear of falling.
|
Observational Model: Cross-Sectional
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Falls Efficacy Scale-International
Délai: Time Frame: Baseline (single assessment)
|
Fear of falling will be assessed using the Falls Efficacy Scale-International (FES-I).
The FES-I is a 16-item questionnaire that evaluates concern about falling during a range of daily activities.
Total scores range from 16 to 64, with higher scores indicating greater fear of falling.
|
Time Frame: Baseline (single assessment)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fatigue Severity Scale (FSS)
Délai: Baseline (single assessment)
|
Fatigue severity will be assessed using the Fatigue Severity Scale (FSS).
The FSS consists of 9 items rated on a 7-point Likert scale.
The total score is calculated as the mean of all items, with higher scores indicating greater fatigue severity.
|
Baseline (single assessment)
|
|
Baseline (single assessment)
Délai: Baseline (single assessment)
|
Balance performance will be evaluated using the Mini-Balance Evaluation Systems Test (Mini-BESTest).
The Mini-BESTest consists of 14 items assessing dynamic balance.
Total scores range from 0 to 28, with higher scores indicating better balance performance.
|
Baseline (single assessment)
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult Scler. 2003 Jun;9(3):219-27. doi: 10.1191/1352458503ms904oa.
- Nilsagard Y, Lundholm C, Denison E, Gunnarsson LG. Predicting accidental falls in people with multiple sclerosis -- a longitudinal study. Clin Rehabil. 2009 Mar;23(3):259-69. doi: 10.1177/0269215508095087.
- Hebert JR, Corboy JR. The association between multiple sclerosis-related fatigue and balance as a function of central sensory integration. Gait Posture. 2013 May;38(1):37-42. doi: 10.1016/j.gaitpost.2012.10.015. Epub 2012 Nov 28.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Uskudar-MS
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .